Concepedia

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD

Tim Dierckx, Bram Verstockt, Séverine Vermeire, Johan Van Weyenbergh

Journal of Crohn s and Colitis · 2018 · 54 citations · 20 references

DOIFull text

Open access

Abstract

GlycA holds promise as a viable serological biomarker for disease activity in IBD, even in patients without elevated CRP, and should therefore be tested in large prospective cohorts.

References

20

R: A Language and Environment for Statistical Computing

R Core Team · 2000 · 352.8K citations · Full text

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt et al. · The Lancet · 2017 · 883 citations

, , +3

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

Andreas Sturm, Christian Maaser, Emma Calabrese et al. · Journal of Crohn s and Colitis · 2018 · 435 citations · Full text

Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons

Krista Fischer, Johannes Kettunen, Peter Würtz et al. · PLoS Medicine · 2014 · 365 citations · Full text

The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection

Scott C. Ritchie, Peter Würtz, Artika P. Nath et al. · Cell Systems · 2015 · 254 citations · Full text

, , +12